DK1490066T3 - Anvendelse af ranolazin til fremstilling af et medikament til behandling af arytmier - Google Patents

Anvendelse af ranolazin til fremstilling af et medikament til behandling af arytmier

Info

Publication number
DK1490066T3
DK1490066T3 DK03723907T DK03723907T DK1490066T3 DK 1490066 T3 DK1490066 T3 DK 1490066T3 DK 03723907 T DK03723907 T DK 03723907T DK 03723907 T DK03723907 T DK 03723907T DK 1490066 T3 DK1490066 T3 DK 1490066T3
Authority
DK
Denmark
Prior art keywords
ranolazine
arrhythmias
drug
manufacture
treatment
Prior art date
Application number
DK03723907T
Other languages
English (en)
Inventor
Luiz Belardinelli
Charles Antzelevitch
Brent Blackburn
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1490066T3 publication Critical patent/DK1490066T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK03723907T 2002-04-04 2003-04-04 Anvendelse af ranolazin til fremstilling af et medikament til behandling af arytmier DK1490066T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37015002P 2002-04-04 2002-04-04
US40829202P 2002-09-05 2002-09-05
US42258902P 2002-10-30 2002-10-30
PCT/US2003/010434 WO2003086401A1 (en) 2002-04-04 2003-04-04 Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias

Publications (1)

Publication Number Publication Date
DK1490066T3 true DK1490066T3 (da) 2008-10-13

Family

ID=29255318

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08004276.5T DK1930007T3 (da) 2002-04-04 2003-04-04 Anvendelse af renolazin til fremstilling af et medikament til behandling af tidlige efterdepolarisationer (EADs)
DK03723907T DK1490066T3 (da) 2002-04-04 2003-04-04 Anvendelse af ranolazin til fremstilling af et medikament til behandling af arytmier

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08004276.5T DK1930007T3 (da) 2002-04-04 2003-04-04 Anvendelse af renolazin til fremstilling af et medikament til behandling af tidlige efterdepolarisationer (EADs)

Country Status (20)

Country Link
US (2) US20030220344A1 (da)
EP (3) EP1490066B1 (da)
JP (1) JP4608217B2 (da)
KR (2) KR20100119804A (da)
CN (2) CN101843619A (da)
AT (2) ATE397932T1 (da)
AU (3) AU2003230810B2 (da)
CA (1) CA2481192C (da)
CY (1) CY1110400T1 (da)
DE (2) DE60332975D1 (da)
DK (2) DK1930007T3 (da)
ES (2) ES2345573T3 (da)
HK (1) HK1120390A1 (da)
IL (1) IL197406A0 (da)
MX (1) MXPA04009637A (da)
NO (1) NO330953B1 (da)
NZ (1) NZ535610A (da)
PT (2) PT1490066E (da)
SI (2) SI1490066T1 (da)
WO (1) WO2003086401A1 (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
MXPA04011530A (es) * 2002-05-21 2005-08-15 Cv Therapeutics Inc Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes.
AU2004303882A1 (en) * 2003-12-18 2005-07-07 Gilead Palo Alto, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
AU2005304421A1 (en) * 2004-11-09 2006-05-18 Gilead Palo Alto, Inc. Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
BRPI0606403A2 (pt) * 2005-01-06 2009-06-23 Cv Therapeutics Inc formulações farmacêuticas com liberação sustentada e seus usos
US20060263427A1 (en) * 2005-05-03 2006-11-23 Roberts Richard H Quinine formulations
WO2008080012A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080214556A1 (en) * 2007-02-13 2008-09-04 Markus Jerling Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
KR20100033490A (ko) * 2007-05-31 2010-03-30 질레드 팔로 알토 인코포레이티드 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진
CA2713521A1 (en) * 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
EP2337559A2 (en) * 2008-09-04 2011-06-29 Gilead Sciences, Inc. Method of treating atrial fibrillation
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
AU2013257706A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014027262A2 (en) * 2012-08-14 2014-02-20 Mahesh Kandula Compositions and methods for the treatment angina and cardiovascular conditions
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
AU2014296145A1 (en) * 2013-08-01 2016-01-28 Gilead Sciences, Inc. Compound and methods for treating long QT syndrome
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
KR101617683B1 (ko) * 2015-01-09 2016-05-03 연세대학교 산학협력단 부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
NZ247044A (en) * 1989-06-23 1997-04-24 Syntex Usa Inc Substituted For Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
EP0720605B1 (en) * 1993-09-24 2001-12-19 University Of British Columbia Aminocyclohexylesters and uses thereof
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
KR20020075801A (ko) * 2000-02-18 2002-10-05 씨브이 쎄러퓨틱스, 인코포레이티드 울혈성 심부전 치료의 부분적 지방산 산화 방지제
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
EP1282436B1 (en) * 2000-05-19 2008-06-11 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with glp-1
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
NZ535610A (en) 2006-05-26
CY1110400T1 (el) 2015-04-29
ES2304507T3 (es) 2008-10-16
JP2005528393A (ja) 2005-09-22
SI1490066T1 (sl) 2008-10-31
US20100004255A1 (en) 2010-01-07
IL197406A0 (en) 2011-07-31
ATE470445T1 (de) 2010-06-15
EP1490066A1 (en) 2004-12-29
CN101843619A (zh) 2010-09-29
EP1930007B1 (en) 2010-06-09
CA2481192C (en) 2012-07-03
EP2198866A1 (en) 2010-06-23
AU2009201065B2 (en) 2011-07-21
AU2009201065A1 (en) 2009-04-09
AU2011202135A1 (en) 2011-05-26
ATE397932T1 (de) 2008-07-15
DE60321550D1 (de) 2008-07-24
KR20100119804A (ko) 2010-11-10
EP1930007A1 (en) 2008-06-11
JP4608217B2 (ja) 2011-01-12
SI1930007T1 (sl) 2010-08-31
WO2003086401A1 (en) 2003-10-23
MXPA04009637A (es) 2005-07-14
ES2345573T3 (es) 2010-09-27
AU2003230810B2 (en) 2009-02-26
EP1490066B1 (en) 2008-06-11
NO330953B1 (no) 2011-08-22
DK1930007T3 (da) 2010-08-30
DE60332975D1 (de) 2010-07-22
US20030220344A1 (en) 2003-11-27
PT1930007E (pt) 2010-08-17
CA2481192A1 (en) 2003-10-23
AU2003230810A1 (en) 2003-10-27
KR20040099395A (ko) 2004-11-26
NO20044783L (no) 2004-11-03
PT1490066E (pt) 2008-07-22
HK1120390A1 (en) 2009-04-03
CN1646127A (zh) 2005-07-27
CN100548300C (zh) 2009-10-14

Similar Documents

Publication Publication Date Title
DK1490066T3 (da) Anvendelse af ranolazin til fremstilling af et medikament til behandling af arytmier
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
GB0223038D0 (en) Therapeutic compounds
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
PL1765388T3 (pl) Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
NO20054714D0 (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
EE04854B1 (et) Oksabispidiinühendid, nende valmistamise meetod ning ravimvorm kasutamiseks südame arütmia raviks ja profülaktikaks
NO20033498D0 (no) Fremgangsmåte for behandling og törking av trevirke
NO20044398L (no) Fotokatalysatorer inneholdende titanoksyd, samt fremgangsmate og anvendelse derav
ZA200609220B (en) Method of treating dry eye disorders and uveitis
EP1667827A4 (en) PROCESS FOR TREATING WOOD
FI20011298A (fi) Puunkäsittelyliuos ja menetelmä puun säilyvyyden parantamiseksi
EP1684735A4 (en) COMPOUNDS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIES INDUCED BY PHYSICAL EXERCISE
DE60224650D1 (de) Vorrichtung zur behandlung von vorhof-fibrillation
ATE444398T1 (de) Fasergebilde mit oberflächenbehandlungszusammensetzung und eine lotionszusammensetzung
DE60326931D1 (de) In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
CY1115214T1 (el) Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων
NO20030057D0 (no) Nye bispidinforbindelser og deres anvendelse ved behandling av hjertearytmier
AU2003249999A8 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours
EE200100674A (et) Bispidiini uued arütmiavastased ühendid, mida kasutatakse südame arütmia ravis
EE200100678A (et) Bispidiini uued arütmiavastased ühendid, mida kasutatakse südame arütmia ravis
ZA200410231B (en) Process and auxiliaries for the treatment of organically tanned leather.